In the last three months, 15 analysts have published ratings on Intra-Cellular Therapies ITCI, offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 9 | 2 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 2 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 4 | 0 | 0 | 0 |
| 3M Ago | 2 | 3 | 2 | 0 | 0 |
Analysts have set 12-month price targets for Intra-Cellular Therapies, revealing an average target of $100.93, a high estimate of $130.00, and a low estimate of $74.00. This current average has increased by 2.78% from the previous average price target of $98.20.
Investigating Analyst Ratings: An Elaborate Study
An in-depth analysis of recent analyst actions unveils how financial experts perceive Intra-Cellular Therapies. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jessica Fye | JP Morgan | Raises | Overweight | $89.00 | $81.00 |
| Ami Fadia | Needham | Maintains | Buy | $100.00 | $100.00 |
| Ami Fadia | Needham | Maintains | Buy | $100.00 | $100.00 |
| Jeffrey Hung | Morgan Stanley | Raises | Overweight | $95.00 | $92.00 |
| Brian Abrahams | RBC Capital | Raises | Outperform | $108.00 | $106.00 |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $130.00 | $130.00 |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $130.00 | $130.00 |
| Charles Duncan | Piper Sandler | Raises | Overweight | $92.00 | $68.00 |
| Jessica Fye | JP Morgan | Raises | Overweight | $81.00 | $79.00 |
| Brian Abrahams | RBC Capital | Lowers | Outperform | $106.00 | $107.00 |
| Charles Duncan | Cantor Fitzgerald | Raises | Overweight | $130.00 | $120.00 |
| Ashwani Verma | UBS | Lowers | Neutral | $79.00 | $83.00 |
| Corinne Jenkins | Goldman Sachs | Lowers | Neutral | $74.00 | $77.00 |
| Ami Fadia | Needham | Maintains | Buy | $100.00 | $100.00 |
| Ami Fadia | Needham | Maintains | Buy | $100.00 | $100.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Intra-Cellular Therapies. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Intra-Cellular Therapies compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Intra-Cellular Therapies's stock. This comparison reveals trends in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Intra-Cellular Therapies's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Intra-Cellular Therapies analyst ratings.
Unveiling the Story Behind Intra-Cellular Therapies
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Intra-Cellular Therapies's Financial Performance
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Intra-Cellular Therapies displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 39.23%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Intra-Cellular Therapies's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -15.03%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Intra-Cellular Therapies's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -2.3%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Intra-Cellular Therapies's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -1.99%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Intra-Cellular Therapies's debt-to-equity ratio is below the industry average. With a ratio of 0.02, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
What Are Analyst Ratings?
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
